Alzheimer's and Parkinson's charities identify new ways to reuse current drugs
Experts say that by repurposing drugs, they can 'increase the shots on target' at tackling the diseases.
This method of drug development could also reduce the time patients are left waiting for new treatments by up to 10 years, they added.
It comes after the NHS spending watchdog rejected the use of new Alzheimer's drugs lecanemab and donanemab for widespread use in the health service.
The drugs were approved for use in the UK last year by the UK's medicines regulator but the NHS spending watchdog, the National Institute for Health and Care Excellence (Nice), said they could not be used in the NHS because the benefits are 'too small' to justify the cost.
Now charities Cure Parkinson's and Alzheimer's Research UK have joined forces to find current drugs that may tackle some of the common biology behind both diseases.
https://x.com/AlzResearchUK/status/1929856926885539966/photo/2
After presentations to the International Linked Clinical Trials (iLCT), which was set up by Cure Parkinson's over a decade ago, experts from both fields will select the most promising drugs for both Parkinson's and dementia, so they can be moved quickly into clinical trials.
Weight loss jabs are already being investigated for their effectiveness in treating symptoms of both diseases and experts hope to uncover more drugs that can have multiple uses.
Semaglutide, the active ingredient for weight loss and diabetes drugs Wegovy and Ozempic, is being examined in clinical trials to see whether it can help patients with Alzheimer's disease or Parkinson's.
Trial results for the Alzheimer's trial are expected to be published later this year.
Dr Sheona Scales, director of research at Alzheimer's Research UK, told the PA news agency that the iLCT project had already been 'hugely successful' with people who have Parkinson's, adding: 'Around 30% of disease modifying therapies that are in clinical trials for Parkinson's disease came through this process.
'What we wanted to do is to build on their knowledge and experience and expertise in order to be able to bring a process similar to that to Alzheimer's disease.'
Dr Scales said that there are some 'common grounds' between Parkinson's and Alzheimer's – both are neurodegenerative diseases and have some 'common biological processes' – such as inflammation, mitochondrial dysfunction and 'protein misfolding' – which could be targets for repurposed drugs.
'Getting multiple drugs that are targeting the disease is really important to us,' she said.
'Testing different types of drugs and getting as many shots on target is important.'
She said: 'Repurposed drugs have already been demonstrated to be safe for use in humans development of new drugs for different diseases is a long process.
'What essentially bringing repurposed drugs does, is help to accelerate the drug development pipeline – it could save between five and 10 years within that process, compared to taking a new drug through clinical trials for the very first time.'
Helen Matthews, chief executive of Cure Parkinson's, said the iLCT was originally set up to identify drugs that can potentially 'slow down, stop or reverse Parkinson's'.
She added: 'It was through this programme that we realised that there were so many drugs that were also being looked at in the dementia field and there were commonalities there in terms of the drugs looking to reduce inflammation, or whatever it might be, there were specific pathways that those drugs were working on that could be beneficial for both disease areas.
'So given that we were already doing the (work) every year, it made sense to join forces in this way, just to add efficiencies.
'Because if you're looking at the same drugs, we'll only do that digging once, you know, only do that compilation of the dossiers once, so that you can actually take the learning for both diseases and then actually look and see which might be beneficial.'
She said that the 'sharing of knowledge and digging' could also be shared with other disease areas, such as MS.
And on lecanemab and donanemab, Dr Scales added: '(These) were the first disease-targeting therapies that have been licensed in the UK, but obviously are not available on the NHS at the moment.
'They showed for the very first time that we were able to alter the course of the disease.
'And what we're looking forward to now is what the next generation of treatments can bring us and how we can target different parts of the disease.'
Dr Lucy Devendra, head of research at Alzheimer's Society, said: 'Repurposing medicines which are already known to be safe can help us find new treatments for the diseases that cause dementia much quicker.
'Although it is still early days, it's encouraging to see a renewed focus on this type of research and development.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
Satellites project could help ‘save lives' and give extreme weather warnings
A series of satellites are set to be launched into space over the next 15 years to help 'save lives' and give early warning of increasingly extreme weather, experts have said. The Metop Second Generation project aims to make weather forecasting more accurate by providing more detailed information for prediction models which will feed into Met Office data. The first satellite, Metop-SG A1, will be launched from French Guiana on Wednesday and start collecting data on weather patterns next year. The European Organisation for the Exploitation of Meteorological Satellites (EUMetSat) and the European Space Agency are leading the project, which will see six satellites sent into a low-earth orbit. The project hopes to improve short-range and long-term forecasts, which will also help scientists monitor increasingly extreme weather across the world. Phil Evans, director general of EUMetSat, said the new satellites would help to save lives by predicting increasingly extreme weather before it happens. He said: 'Extreme weather has cost Europe hundreds of billions of euros and tens of thousands of lives over the past 40 years — storms like Boris, Daniel and Hans, record heatwaves and fierce wildfires are just the latest reminders. 'The launch of Metop-SG A1 is a major step forward in giving national weather services in our member states sharper tools to save lives, protect property and build resilience against the climate crisis.' Once in use, the satellites could see improved forecasts for up to 10 days ahead in Europe and worldwide. The data can also help short-range forecasts and enable experts to spot tell-tale signs of early storm development and other high-impact weather events, especially those at higher latitudes. On the satellite will be a tracker called the Copernicus Sentinel 5 mission, which will primarily be used for monitoring air quality and long-term climate monitoring. The satellite will station itself about 800km above the Earth and complete one full orbit every 100 minutes, passing close to the north and south poles – enabling it to take images of the entire globe over the course of the day. As well as imaging, the satellite will use other equipment like sounders in order to collect data on temperature, precipitation, clouds, winds, pollution and other factors to predict weather. This information will be fed back to stations such as the newly-installed satellite tracking dish at the Met Office headquarters in Exeter. This will be 'absolutely vital' for weather forecasters, said Simon Keogh, head of space applications at the Met Office. He said: 'We know how important satellite data is for forecast accuracy, with around a quarter of existing accuracy coming from this source. 'The next generation of these satellites is important not only for maintaining existing accuracy as old systems go offline, but also for enhancing observations for the next generation of weather forecasts. 'This project is absolutely vital as we make sure we can continue to deliver more accurate forecasts for the next five days and beyond.' UK science minister Lord Vallance said: 'Our weather is becoming more extreme and more unpredictable. This launch is the latest result of the UK investing with European partners to bolster weather predictions so we can keep up with our changing climate. 'Harnessing the world-class insights from this satellite will improve our ability to predict high-impact weather events even earlier. This will protect our infrastructure, our economy and save lives, keeping our plan for change on track.' On Tuesday, the fourth heatwave of the summer was announced, with organisations issuing amber health warnings and a possible risk to life from the high temperatures. The world experienced its third-warmest July on record this year, experts said, with heat and deadly floods throughout the month.
Medscape
37 minutes ago
- Medscape
Growth Charts for Twins Improve Perinatal Risk Prediction
TOPLINE: New customised growth charts for twins (GROW-T), adjusted for maternal characteristics, more accurately predicted a small-for-gestational age (SGA)-associated risk for adverse perinatal outcomes than charts for singletons (GROW-S). METHODOLOGY: Researchers developed customised growth charts for twin pregnancies and compared them with singleton charts to evaluate their ability to identify SGA twins who are at an increased risk for adverse perinatal outcomes. They evaluated 8457 twin pregnancies (16,914 foetuses) from 127 NHS hospitals in the UK from January 2015 to February 2025, representing approximately two thirds of all NHS units. A mixed-effects linear regression analysis was performed to determine pregnancy-specific optimal weights at 37 weeks. Researchers compared GROW-T with GROW-S by calculating rates of the SGA-associated risk for stillbirth and adverse neonatal outcomes, such as the need for resuscitation, an Apgar score < 7 at 5 minutes, admission to the NICU, or neonatal death, using generalised estimating equations. TAKEAWAY: At 37 weeks, the average optimal weight of a twin was 389 g less than that of an equivalent singleton foetus. By pregnancy, 24.6% vs 64.9% of twins were classified as those with SGA (< 10th centile) according to GROW-T vs GROW-S; when analysed by individual foetuses, 13.8% vs 44.4% of twins were classified as those with SGA according to GROW-T vs GROW-S. Twins designated as SGA on the basis of GROW-T (odds ratio [OR], 7.2; 95% CI, 4.8-10.8) had a higher risk for stillbirth than those designated as SGA on the basis of GROW-S (OR, 2.8; 95% CI, 1.9-4.1). Twins classified as those with SGA on the basis of GROW-T had an increased need for resuscitation (OR, 1.3; 95% CI, 1.1-1.7), a lower Apgar score (< 7) at 5 minutes (OR, 1.8; 95% CI, 1.2-2.6), higher NICU admissions (OR, 1.3; 95% CI, 1.0-1.6), and an increased risk for neonatal death (OR, 5.4; 95% CI, 1.3-23.5). IN PRACTICE: "Our results add to the increasing evidence for adoption of twin specific charts," the authors wrote. "While adoption of twin specific charts is timely, implementation ought to be accompanied by evaluation in practice to monitor safety in different health service environments," they added. SOURCE: This study was led by Jason Gardosi, MD, Perinatal Institute, Birmingham, England, and was published online on August 01, 2025, in the American Journal of Obstetrics & Gynecology. LIMITATIONS: Ultrasound estimates of foetal weight in twins can be systematically overestimated, potentially affecting the accuracy of growth assessments. Chorionicity was not reported in the study cohort; however, the difference between growth curves of monochorionic and dichorionic twins was considered too small to be clinically relevant. DISCLOSURES: No funding information was provided for the study. All authors reported being employees of the Perinatal Institute, Birmingham, England. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Medscape
37 minutes ago
- Medscape
Common Phthalate Tied to Coronary Risk in Car Plant Workers
TOPLINE: Exposure to monoethyl phthalate (MEP) — a chemical commonly found in industrial and personal care products — was associated with a substantially elevated risk for subclinical coronary atherosclerosis among men working in a car assembly unit. METHODOLOGY: Researchers conducted a cross-sectional study to assess whether urinary phthalates showed any association with subclinical coronary atherosclerosis. They included 1119 Spanish male workers (mean age, 50.9 years) from a car assembly plant. A total of 11 urinary phthalate metabolites were measured using liquid chromatography coupled to tandem mass spectrometry. Participants underwent CT scans between January 2011 and December 2014 to determine coronary artery calcium; subclinical coronary atherosclerosis was defined as a coronary artery calcium score ≥ 100 Agatston units. TAKEAWAY: Subclinical coronary atherosclerosis was identified in 114 men (10.2%). MEP was the phthalate with the highest median concentration; men with subclinical coronary atherosclerosis had a higher median MEP concentration than those without the condition (126.1 vs 99.3 µg/g creatinine). Each 1-unit increase in the natural logarithm of MEP was associated with a 21% higher prevalence of subclinical coronary atherosclerosis (adjusted odds ratio, 1.21; 95% CI, 1.02-1.44). Monoisobutyl phthalate and mono-n-butyl phthalate showed a positive association with the condition, but this association did not reach statistical significance. IN PRACTICE: "Educational strategies might complement cardiovascular prevention by promoting behaviors that reduce phthalate exposure, such as choosing fragrance-free products, preferring glass containers over plastics, and minimizing ultraprocessed food consumption," the researchers noted. SOURCE: This study was led by Diana María Mérida, Universidad Autónoma de Madrid, Madrid, Spain. It was published online on August 06, 2025, in The American Journal of Preventive Cardiology. LIMITATIONS: This cross-sectional study could not imply whether phthalates caused subclinical coronary atherosclerosis. The findings may not be generalisable to women, older adults, or individuals from different occupational backgrounds or socioeconomic groups. Urinary concentrations of phthalate metabolites reflect only short-term exposure, but chronic diseases are usually linked to long-term exposures. DISCLOSURES: This study was supported by the Health Research Fund from the State Secretary of R+D and FEDER/FSE, Instituto de Salud Carlos III, Spain. The authors reported having no conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
